On February 12, 2019 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reported that a presentation of data from the pivotal Phase 3 SIERRA trial of Iomab-B has been selected as one of four late breaking oral presentations at the 2019 TCT or Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, which is being held February 20 – 24 in Houston, Texas (Press release, Actinium Pharmaceuticals, FEB 12, 2019, View Source [SID1234533255]). In addition, three abstracts related to Actinium’s targeted conditioning pipeline have been accepted for poster presentations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sandesh Seth, Chairman and CEO of Actinium, said, "TCT is the ideal venue for us to present data and highlight our targeted conditioning programs as it is the pre-eminent medical meeting focused on bone marrow transplant and cellular therapy. We are excited to have multiple opportunities to highlight clinical data for Iomab-as well as update on Iomab-ACT, our newest program focused on lymphodepletion prior to CAR-T. In addition, we are involved with several events, educational and otherwise, that will enable us to educate a broad audience of investigators, researchers and potential partners about the SIERRA trial and our highly differentiated multi-disease, multi-target targeted conditioning pipeline. We expect this meeting to be a highly productive and consequential one for our company."
Highlights of Actinium’s key meeting activities are:
Late Breaking Oral Presentation
Title:
Novel Re-Induction and Anti-CD45 Targeted Conditioning with Iodine (131I) Apamistamab [Iomab-B] Yields Encouraging Results in Older Patients with Active, Relapsed or Refractory AML: Safety & Feasibility Data from the Prospective Randomized Phase III SIERRA Trial
Presenter:
Sergio Giralt, MD, Chief Attending Physician, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center
Time:
Sunday, February 24th, 12:30-12:45 PM CT
Location:
Hilton Americas – Grand Ballroom A
Poster Presentations
Poster Title:
Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy or CAR-T
Presenter:
Dale Ludwig, PhD, Chief Scientific Officer, Actinium Pharmaceuticals, Inc.
Time:
Wednesday, February 20th, 6:45 – 7:45 PM CT
Location:
George R. Brown Convention Center – GRB Exhibit Hall B3
Poster Title:
Survival of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients Receiving Stem Cell Transplantation (SCT)
Presenter:
Rajneesh Nath, MD, Director Bone Marrow Transplant & Acute Leukemia Program, Banner MD Anderson Cancer Center
Time:
Wednesday, February 20th, 6:45 – 7:45 PM CT
Location:
George R. Brown Convention Center – GRB Exhibit Hall B3
Poster Title:
Burden of Hospitalization in Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Presenter:
Vijay Reddy, MD, PhD, Vice President, Clinical Development and Head of Bone Marrow Transplant, Actinium Pharmaceuticals, Inc.
Time:
Wednesday, February 20th, 6:45 – 7:45 PM CT
Location:
George R. Brown Convention Center – GRB Exhibit Hall B3
TCT 2019 Satellite Symposium
Satellite symposia are attended by nearly 2,000 physicians, scientists and allied health professionals working in blood and marrow transplantation in BMT programs throughout the United States, Canada and over 30 other countries.
Title:
Integrating Innovative Therapeutics with Allogeneic HSCT in AML: Insights and Evidence from Induction to Maintenance
Presenters:
James Foran, MD, Associate Professor of Medicine, Mayo Clinic and Alexander Perl, MD, Associate Professor of Medicine, University of Pennsylvania
Time:
Saturday, February 23rd, 12:30 – 1:30 PM
Location:
George R. Brown Convention Center, Grand Ballroom ABC
Dr. Mark Berger, Chief Medical Officer of Actinium commented, "TCT brings together the close-knit community of BMT and CAR-T physicians and health professionals resulting in an incredibly productive and valuable meeting. We are honored to have the opportunity to share so much of our research and clinical programs with the meeting attendees this year. Given the recent promising data presented at ASH (Free ASH Whitepaper) for Iomab-B, our late breaking oral presentation for Iomab-B and the recent launch of our Iomab-ACT program for CAR-T, I expect this year to be our most productive and rewarding conference yet."
About Transplantation & Cellular Therapy Meetings (TCT)
TCT, formerly known as the BMT Tandem Meetings, are the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Each year the conference brings together several thousand investigators, clinicians, researchers, nurses and other allied health professionals from over 500 transplant centers from over 50 countries around a full scientific program focused on bone marrow transplant and cellular therapies.